Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

THE ROLE OF LABORATORY BIOMARKERS IN PREDICTING THE EFFICIENCY OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: NEW EVIDENCE

A. S. Avdeeva
D. A. Kusevich

July 2017

Rheumatoid arthritis (RA) is the most common and severe chronic joint inflammatory disease leading t...

The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition

Bensalem, Amina
Cartron, Guillaume
Specks, Ulrich
Mulleman, Denis
Gyan, Emmanuel
Cornec, Divi
Desvignes, Celine
Casasnovas, Olivier
Lamy, Thierry
Leprêtre, Stéphane
Paintaud, Gilles
Ternant, David

November 2021

International audienceBACKGROUND AND OBJECTIVES: Rituximab is an anti-CD20 monoclonal antibody appro...

POPULATION PHARMACOKINETICS OF RITUXIMAB IN RA PATIENTS: COMBINING TWO PHASE II STUDIES

November 2014

Q Rituximab, a B cell-specific, CD20-targeted therapeutic monoclonal antibody, is approved for the t...

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Lioger, Bertrand
Edupuganti, Soujanya Ratna
Mulleman, Denis
Passot, Christophe
Desvignes, Celine
Bejan-Angoulvant, Theodora
Thibault, Gilles
Gouilleux-Gruart, Valérie
Mélet, Julien
Paintaud, Gilles
Ternant, David

August 2017

International audienceRituximab is a monoclonal antibody directed against CD20, which is approved in...

Long-term treatment of rheumatoid arthritis with rituximab and the influence on the immunoglobulin concentration

Kemperink, H.

January 2010

Objective Biologicals are drugs composed of proteins directed against specific cells or cytokines. B...

Rituximab levels are associated with the B cell homeostasis but not with the clinical response in patients with rheumatoid arthritis

Díaz Torne, César
Ortiz, Maria Àngels
Sarmiento, Mónica
Díaz-López, César
Corominas, Hèctor
Casademont i Pou, Jordi
Vidal, Silvia
Universitat Autònoma de Barcelona

February 2021

To study the levels of rituximab (RTX) and anti-RTX antibodies (ARAs) in patients with rheumatoid ar...

The anti-CD20 antibody rituximab reduces the Th17 cell response.

van de Veerdonk, Frank L
Lauwerys, Bernard
Marijnissen, Renoud J
Timmermans, Kim
Di Padova, Franco
Koenders, Marije I
Gutierrez-Roelens, Ilse
Durez, Patrick
Netea, Mihai G
van der Meer, Jos W M
van den Berg, Wim B
Joosten, Leo A B

January 2011

Rituximab has been shown to be successful in the treatment of rheumatoid arthritis (RA), and this un...

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis

Thurlings, R.M.
Teng, O.
Vos, K.
Gerlag, D.M.
Aarden, L.
Stapel, S.O.
van Laar, J.M.
Tak, P.P.
Wolbink, G.J.

January 2010

Objectives: To analyse whether persistence of synovial B lineage cells and lack of clinical response...

CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis

Bensalem, Amina
Mulleman, Denis
Thibault, Gilles
Azzopardi, Nicolas
Goupille, Philippe
Paintaud, Gilles
Ternant, David

August 2019

International audienceRituximab is approved in rheumatoid arthritis (RA). A substantial decrease in ...

THE ROLE OF LABORATORY BIOMARKERS IN PREDICTING THE EFFICIENCY OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: NEW EVIDENCE

A. S. Avdeeva
D. A. Kusevich

July 2017

Rheumatoid arthritis (RA) is the most common and severe chronic joint inflammatory disease leading t...

The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition

Bensalem, Amina
Cartron, Guillaume
Specks, Ulrich
Mulleman, Denis
Gyan, Emmanuel
Cornec, Divi
Desvignes, Celine
Casasnovas, Olivier
Lamy, Thierry
Leprêtre, Stéphane
Paintaud, Gilles
Ternant, David

November 2021

International audienceBACKGROUND AND OBJECTIVES: Rituximab is an anti-CD20 monoclonal antibody appro...

POPULATION PHARMACOKINETICS OF RITUXIMAB IN RA PATIENTS: COMBINING TWO PHASE II STUDIES

November 2014

Q Rituximab, a B cell-specific, CD20-targeted therapeutic monoclonal antibody, is approved for the t...

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Lioger, Bertrand
Edupuganti, Soujanya Ratna
Mulleman, Denis
Passot, Christophe
Desvignes, Celine
Bejan-Angoulvant, Theodora
Thibault, Gilles
Gouilleux-Gruart, Valérie
Mélet, Julien
Paintaud, Gilles
Ternant, David

August 2017

International audienceRituximab is a monoclonal antibody directed against CD20, which is approved in...

Long-term treatment of rheumatoid arthritis with rituximab and the influence on the immunoglobulin concentration

Kemperink, H.

January 2010

Objective Biologicals are drugs composed of proteins directed against specific cells or cytokines. B...

Rituximab levels are associated with the B cell homeostasis but not with the clinical response in patients with rheumatoid arthritis

Díaz Torne, César
Ortiz, Maria Àngels
Sarmiento, Mónica
Díaz-López, César
Corominas, Hèctor
Casademont i Pou, Jordi
Vidal, Silvia
Universitat Autònoma de Barcelona

February 2021

To study the levels of rituximab (RTX) and anti-RTX antibodies (ARAs) in patients with rheumatoid ar...

The anti-CD20 antibody rituximab reduces the Th17 cell response.

van de Veerdonk, Frank L
Lauwerys, Bernard
Marijnissen, Renoud J
Timmermans, Kim
Di Padova, Franco
Koenders, Marije I
Gutierrez-Roelens, Ilse
Durez, Patrick
Netea, Mihai G
van der Meer, Jos W M
van den Berg, Wim B
Joosten, Leo A B

January 2011

Rituximab has been shown to be successful in the treatment of rheumatoid arthritis (RA), and this un...

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis

Thurlings, R.M.
Teng, O.
Vos, K.
Gerlag, D.M.
Aarden, L.
Stapel, S.O.
van Laar, J.M.
Tak, P.P.
Wolbink, G.J.

January 2010

Objectives: To analyse whether persistence of synovial B lineage cells and lack of clinical response...

CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis

Bensalem, Amina
Mulleman, Denis
Thibault, Gilles
Azzopardi, Nicolas
Goupille, Philippe
Paintaud, Gilles
Ternant, David

August 2019

International audienceRituximab is approved in rheumatoid arthritis (RA). A substantial decrease in ...

THE ROLE OF LABORATORY BIOMARKERS IN PREDICTING THE EFFICIENCY OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: NEW EVIDENCE

A. S. Avdeeva
D. A. Kusevich

July 2017

Rheumatoid arthritis (RA) is the most common and severe chronic joint inflammatory disease leading t...

The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition

Bensalem, Amina
Cartron, Guillaume
Specks, Ulrich
Mulleman, Denis
Gyan, Emmanuel
Cornec, Divi
Desvignes, Celine
Casasnovas, Olivier
Lamy, Thierry
Leprêtre, Stéphane
Paintaud, Gilles
Ternant, David

November 2021

International audienceBACKGROUND AND OBJECTIVES: Rituximab is an anti-CD20 monoclonal antibody appro...

POPULATION PHARMACOKINETICS OF RITUXIMAB IN RA PATIENTS: COMBINING TWO PHASE II STUDIES

November 2014

Q Rituximab, a B cell-specific, CD20-targeted therapeutic monoclonal antibody, is approved for the t...

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Abstract

Extracted data

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Abstract

Extracted data

Related items

Related items